Organon & Co | OGN - Operating Profit


Organon & Co reported $388M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Celltrion KRW 301.04B 58.57B Sep/2025
Cspc Pharmaceutical CNY 1.22B 60.54M Sep/2025
Deva Holding AS TRY 964.87M 240.32M Sep/2023
Dianthus Therapeutics USD -40.29M 5.36M Sep/2025
Divis Laboratories Ltd INR 7.72B 30M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Glaxosmithkline GBP 3.76B 1.32B Sep/2025
Kangmei Pharma CNY -26.7M 43.13M Sep/2025
Knight Therapeutics CAD 2.94M 2.4M Sep/2025
Malin Corporation EUR -1.1M 400K Dec/2024
Medical Developments International AUD -36K 444K Dec/2025
Merck USD 6.24B 318M Dec/2025
Neuren Pharmaceuticals AUD 17.01M 11.56M Dec/2025
Novartis USD 4.58B 879M Sep/2025
Organigram Holdings CAD -28.05M 7.76M Sep/2025
Organon & Co USD 388M 62M Sep/2025
Ovoca Bio EUR -5.65M 3.45M Jun/2022
Pharma Mar EUR 43.61M 47.57M Dec/2025
Qiagen NV USD 121.88M 15.41M Dec/2025
Sartorius EUR 150.1M 11.7M Sep/2025
Sino Biopharmaceutical CNY 5.18B 3.32B Jun/2025
Tilray USD -20.01M 9.34M Sep/2025